GERMAN EXCELLENCE

translumina
LIMITLESS POSSIBILITIES

Yukon Choice Flex

Sirolimus Eluting Coronary Stent System

Finding ways to the true joys of life.

Yukon Choice **Flex**

Sirolimus Eluting Coronary Stent System

Advanced platform for redefining flexibility in tortuous anatomy

Ideal Flexible Approach

Yukon Choice Flex offers new generation delivery system with ‘Flexi’ platform providing unmatched delivery in most tortuous vessels.

Enhanced Delivery System

The customized 2-Connector stent design of Yukon Choice Flex with thinner structural elements confirms for optimal deliverability.

Proprietary Hypotube

The new shaft design offers optimal force transfer with excellent push-ability and kink resistance allowing high manoeuvrability, justifying its use for the most tortuous vessels.



10 YEARS
CLINICAL DATA OF EFFICACY & SAFETY

In this unique long term analysis at 10 years,
Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.



Primary End Point



Definite /Probable stent thrombosis

Comparison of clinical outcomes at 10 years in patients treated with new-generation BP-SES versus new-generation PP-EES versus early generation SES.

*As per Clinical data with SS stent using similar microporous surface and drug coating technology

translumina
LIMITLESS POSSIBILITIES

Unmatched Safety- In Complex Patients Subset

Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in **patients with diabetes:** a pooled analysis of individual patient data from 3 randomised trials

International Journal of CARDIOLOGY

At 4 years, Biodegradable Polymer DES Yukon showed significantly lower rates of Stent Thrombosis compared to Durable Polymer DES in patients with Diabetes Mellitus.



Secondary safety end point: definite or probable stent thrombosis

Long-term outcomes of biodegradable versus durable polymer drug-eluting stents **in patients with acute ST-segment elevation myocardial infarction:** a pooled analysis of individual patient data from three randomised trials

EuroIntervention

At 4 years, Biodegradable Polymer DES compared to Durable Polymer SES demonstrated improved overall clinical outcome, reduced need for revascularisation as well as lower incidence of cardiac death or MI and reduced stent thrombosis in patients with STEMI.



Definite or probable stent thrombosis for the pooled population in each of the treatment groups.
CI: confidence interval; HR: hazard ratio

New generation DES providing synergy of biodegradable polymer with microporous surface to enhance optimal performance



Less Polymeric Load Compared To Other DES

- One million pores per cm^2 with average depth of 2 µm ensures optimum drug release with minimal use of polymer
- Top coat with Shellac Resin ensures better polymer-drug binding with negligible polymer flaking during stent expansion
- Drug and polymer are co-released in 6-9 months leaving behind bare metal stent surface

Better Endothelialisation & Superior Strut Coverage

- Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue
- No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis

translumina
LIMITLESS POSSIBILITIES

Yukon Choice Flex

Sirolimus Eluting Coronary Stent System

PRODUCT MATRIX / ORDERING INFORMATION*

Stent Ø [mm]	Stent length [mm] & Article number							
	8	12	16	18	21	24	28	32
Ø 2.00	YCFX2008	YCFX2012	YCFX2016	YCFX2018	YCFX2021	YCFX2024	YCFX2028	YCFX2032
Ø 2.50	YCFX2508	YCFX2512	YCFX2516	YCFX2518	YCFX2521	YCFX2524	YCFX2528	YCFX2532

Stent Ø [mm]	Stent length [mm] & Article number								
	8	12	16	18	21	24	28	32	40
Ø 2.75	YCFX2708	YCFX2712	YCFX2716	YCFX2718	YCFX2721	YCFX2724	YCFX2728	YCFX2732	YCFX2740
Ø 3.00	YCFX3008	YCFX3012	YCFX3016	YCFX3018	YCFX3021	YCFX3024	YCFX3028	YCFX3032	YCFX3040
Ø 3.50	YCFX3508	YCFX3512	YCFX3516	YCFX3518	YCFX3521	YCFX3524	YCFX3528	YCFX3532	YCFX3540
Ø 4.00	YCFX4008	YCFX4012	YCFX4016	YCFX4018	YCFX4021	YCFX4024	YCFX4028	YCFX4032	YCFX4040

* Please contact our Customer Care for available sizes

COMPLIANCE CHART

Balloon Ø [mm]	Pressure [bar/10^5 Pa]														
						NP					RBP				
	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Ø 2.00	1.83	1.87	1.90	1.93	1.96	2.00	2.03	2.06	2.10	2.13	2.16	2.20	2.23	2.26	2.29
Ø 2.50	2.33	2.36	2.40	2.43	2.47	2.50	2.53	2.57	2.60	2.64	2.67	2.70	2.74	2.77	2.81
Ø 2.75	2.58	2.61	2.65	2.68	2.71	2.75	2.78	2.81	2.85	2.88	2.91	2.94	2.98	3.01	3.04
Ø 3.00	2.81	2.85	2.89	2.92	2.96	3.00	3.04	3.07	3.11	3.15	3.18	3.22	3.26	3.29	3.33
Ø 3.50	3.29	3.34	3.38	3.42	3.46	3.50	3.55	3.59	3.63	3.67	3.71	3.76	3.80	3.84	3.88
Ø 4.00	3.75	3.80	3.85	3.90	3.95	4.00	4.06	4.11	4.16	4.21	4.26	4.31	4.36	4.41	4.46

TECHNICAL DATA

Cobalt Chromium Alloy (L605)			
Crossing Profile (Ø 2.5 mm)	0.035" / 0.89 mm	Entry Profile	0.016" / 0.41 mm
Strut Thickness (Ø 2.5 mm)	0.0027" / 68 µm (SV)	Proximal Shaft Diameter	1.9 F
	0.0031" / 79 µm (MV)	Distal Shaft Diameter	2.7 F
Metallic Surface Area	9.1 - 14.9%	Recommended Guide Wire	0.014"
Balloon Marker Material	Platinum / Iridium	Guiding Catheter	min. 5 F

CE 1434

Manufactured By:
Translumina Therapeutics LLP
Plot No. 12, Pharmacity, Selaqui, Dehradun 248 197
(Uttarakhand) India
Drug Manufacturing License No. 12/UA/SC/P-2016

Registered Office:
Translumina Therapeutics LLP
Ground Floor, Metro Tower, LSC MOR Land,
New Rajinder Nagar, New Delhi 110 060 - India

Under Technological Collaboration With:
Translumina GmbH
Neue Rottenburger Strasse 50,
D-72379 Hechingen, Germany

Endomedical S.R.L.
MEDICINA CARDIOVASCULAR

Importador exclusivo para toda la Argentina
www.endomedical.com.ar
Atencion al cliente: ventas@endomedical.com.ar
Contacto: 3414280440

*Please refer to the **Instructions for Use** supplied with these devices for indications, contraindications, adverse effects, suggested procedures, warnings and precautions.*

Doc.Ref.No.YCFX-BC Issue01, Revision 06